Fierce Pharma Asia—Merck's oral GLP-1 play; Astellas' gene therapy deal; Betta's FDA nod
Merck in-licensed a preclinical oral GLP-1 candidate from China's Hansoh Pharma. Astellas doubled down in gene therapy with a viral capsid deal with Sangamo Therapeutics. Betta Pharma's Ensacove became the first innovative targeted lung cancer med …